| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2014.60.0320 |
| P698 | PubMed publication ID | 26282658 |
| P50 | author | Yung-Jue Bang | Q16180903 |
| Seock-Ah Im | Q58821370 | ||
| Jae Yong Cho | Q59684302 | ||
| Yeul Hong Kim | Q98617374 | ||
| P2093 | author name string | Woo Ho Kim | |
| Kyung Hee Lee | |||
| Dae Young Zang | |||
| Eun-Kee Song | |||
| Joon Oh Park | |||
| Keun-Wook Lee | |||
| Mark J O'Connor | |||
| Xiaolu Yin | |||
| Darren Hodgson | |||
| Anitra Fielding | |||
| Hoo Geun Chun | |||
| Jacqui Rowbottom | |||
| P433 | issue | 33 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | paclitaxel | Q423762 |
| phase II clinical trial | Q42824440 | ||
| olaparib | Q7083106 | ||
| P304 | page(s) | 3858-3865 | |
| P577 | publication date | 2015-08-17 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer | |
| P478 | volume | 33 |
| Q33618910 | "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors |
| Q36129160 | 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells |
| Q92105271 | A Bayesian Network Meta-Analysis for Identifying the Optimal Taxane-Based Chemotherapy Regimens for Treating Gastric Cancer |
| Q48232258 | A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma |
| Q36215991 | A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? |
| Q37628924 | ATM protein is deficient in over 40% of lung adenocarcinomas. |
| Q90399238 | ATM-Deficient Cancers Provide New Opportunities for Precision Oncology |
| Q37633188 | ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib |
| Q47113548 | Actionable gene-based classification toward precision medicine in gastric cancer. |
| Q39091817 | Advanced gastric adenocarcinoma: optimizing therapy options. |
| Q39183442 | Advances and challenges in targeting FGFR signalling in cancer. |
| Q37637845 | An unexpected N-terminal loop in PD-1 dominates binding by nivolumab |
| Q38257125 | An update on PARP inhibitors--moving to the adjuvant setting |
| Q89953401 | Ataxia telangiectasia mutated (ATM), could it be another useful biomarker for the successful treatment with the poly (ADP-ribose) polymerase inhibitor? |
| Q55478403 | Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. |
| Q28066550 | Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers |
| Q90684019 | Bioinformatic analysis suggests that UGT2B15 activates the Hippo‑YAP signaling pathway leading to the pathogenesis of gastric cancer |
| Q38575013 | Biomarkers and novel agents in esophago-gastric cancer: are we making progress? |
| Q37573430 | Biomarkers come of age: PD1 in the frontline and cell cycle therapy swells the ranks of personalised therapy in the European Society of Medical Oncology (ESMO) congress, Copenhagen, 7-10 October 2016. |
| Q39038994 | Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety |
| Q38815071 | Chemotherapy for advanced gastric cancer: future perspective in Japan |
| Q41539026 | Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function |
| Q26741530 | Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma |
| Q26785665 | Clinical utility of ramucirumab in advanced gastric cancer |
| Q100941240 | Combinatorial Approaches to Enhance DNA Damage Following Enzyme-mediated Depletion of L-Cyst(e)ine for Treatment of Pancreatic Cancer |
| Q26780298 | Companion diagnostics for the targeted therapy of gastric cancer |
| Q98189590 | Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models |
| Q89763784 | Comprehensive pharmacogenomic characterization of gastric cancer |
| Q64120426 | Computational analysis of data from a genome-wide screening identifies new functional interactors as potential therapeutic targets |
| Q39453613 | Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma |
| Q26745453 | Current and emerging therapies in unresectable and recurrent gastric cancer |
| Q34962039 | Current status of novel agents in advanced gastroesophageal adenocarcinoma |
| Q47155297 | Current status of poly(ADP-ribose) polymerase inhibitors and future directions. |
| Q26776513 | DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer |
| Q92814129 | Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib |
| Q92802562 | Development of an Immunohistochemical Assay to Detect the Ataxia-Telangiectasia Mutated (ATM) Protein in Gastric Carcinoma |
| Q52887500 | Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts |
| Q26781792 | Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis |
| Q89653832 | Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating Mutation |
| Q38740969 | Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions |
| Q57111080 | Emerging Therapies in the Management of Advanced-Stage Gastric Cancer |
| Q39343374 | Gastric adenocarcinoma. |
| Q38749038 | Gastric cancer management: Kinases as a target therapy |
| Q60924983 | Genomic loss of heterozygosity and survival in the REAL3 trial |
| Q91525806 | Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients |
| Q38602669 | In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients |
| Q38856683 | Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer. |
| Q54983582 | Integrating genomic information and signaling dynamics for efficient cancer therapy. |
| Q27853007 | Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines |
| Q50127782 | Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. |
| Q50150279 | Missing a GOLDen opportunity in gastric cancer. |
| Q33696201 | Molecular classifications of gastric cancers: Novel insights and possible future applications |
| Q38772049 | Monoclonal antibodies for treating gastric cancer: promises and pitfalls |
| Q35064299 | Mutation at intronic repeats of the ataxia-telangiectasia mutated (ATM) gene and ATM protein loss in primary gastric cancer with microsatellite instability |
| Q104515440 | Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database |
| Q38788554 | Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation |
| Q26738548 | New advances in targeted gastric cancer treatment |
| Q38759129 | New agents on the horizon in gastric cancer |
| Q26992272 | Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity |
| Q64990976 | Next-generation sequencing and biomarkers for gastric cancer: what is the future? |
| Q53750080 | Novel pharmaceutical treatment approaches for gastric cancer |
| Q26765208 | Novel targets in the treatment of advanced gastric cancer: a perspective review |
| Q42091980 | Novel therapy for advanced gastric cancer |
| Q47440559 | Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial |
| Q89659933 | PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation |
| Q37307055 | PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets |
| Q57792112 | PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines |
| Q64983568 | PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer. |
| Q38842137 | Personalised Treatment in Gastric Cancer: Myth or Reality? |
| Q39453553 | Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies |
| Q61443498 | Phase I clinical study of oral olaparib in pediatric patients with refractory solid tumors: study protocol |
| Q36558421 | Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer |
| Q47139613 | Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer |
| Q99708836 | Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress |
| Q55603677 | Proposed Molecular and miRNA Classification of Gastric Cancer. |
| Q64912862 | Recent advances in the management of gastric adenocarcinoma patients. |
| Q42673155 | Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials |
| Q88428875 | Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer |
| Q30249003 | Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature. |
| Q38750633 | Second-line chemotherapy for patients with advanced gastric cancer. |
| Q55223567 | Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects. |
| Q26778027 | Second-line treatment of metastatic gastric cancer: Current options and future directions |
| Q89969652 | Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy |
| Q26779217 | State of the art management of metastatic gastroesophageal cancer |
| Q57793601 | State-of-the-art strategies for targeting the DNA damage response in cancer |
| Q40961505 | Suberoylanilide hydroxamic acid sensitizes neuroblastoma to paclitaxel by inhibiting thioredoxin-related protein 14-mediated autophagy. |
| Q48218378 | Susceptibility of ATM-deficient pancreatic cancer cells to radiation. |
| Q89578157 | TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy |
| Q38653626 | Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions |
| Q48499391 | Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer |
| Q37634102 | Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. |
| Q38834760 | Targeting deficient DNA damage repair in gastric cancer. |
| Q46386898 | The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells |
| Q58790609 | The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials |
| Q90402575 | The evolving immunotherapeutic landscape in advanced oesophagogastric cancer |
| Q37457827 | Tspan5 is an independent favourable prognostic factor and suppresses tumour growth in gastric cancer |
| Q41158692 | Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia |
| Q41552673 | Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. |
| Q50138423 | Use of olaparib in patients with advanced gastric cancer |
| Q50138421 | Use of olaparib in patients with advanced gastric cancer - Authors' reply |
| Q90003727 | Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers |
| Q45071253 | Vitamin D Receptor Signaling and Cancer |
Search more.